Hortobagyi GN - Search Results

1

Novel Prognostic Staging System for Patients With De Novo Metastatic Breast Cancer.

Plichta JK, Thomas SM, Hayes DF, Chavez-MacGregor M, Allison K, de Los Santos J, Fowler AM, Giuliano AE, Sharma P, Smith BD, van Eycken E, Edge SB, Hortobagyi GN. Plichta JK, et al. Among authors: hortobagyi gn. J Clin Oncol. 2023 May 10;41(14):2546-2560. doi: 10.1200/JCO.22.02222. Epub 2023 Mar 21. J Clin Oncol. 2023. PMID: 36944149 Free PMC article.

2

Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer.

Buzdar AU, Hortobagyi GN, Kau SW, Smith TL, Fraschini G, Holmes FA, Gutterman JU, Hug VM, Singletary SE, Ames FC, et al. Buzdar AU, et al. Among authors: hortobagyi gn. J Clin Oncol. 1992 Oct;10(10):1540-6. doi: 10.1200/JCO.1992.10.10.1540. J Clin Oncol. 1992. PMID: 1403033 Clinical Trial.

3

Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support.

Dunphy FR, Spitzer G, Buzdar AU, Hortobagyi GN, Horwitz LJ, Yau JC, Spinolo JA, Jagannath S, Holmes F, Wallerstein RO, et al. Dunphy FR, et al. Among authors: hortobagyi gn. J Clin Oncol. 1990 Jul;8(7):1207-16. doi: 10.1200/JCO.1990.8.7.1207. J Clin Oncol. 1990. PMID: 2358837 Clinical Trial.

4

A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer.

Hortobagyi GN, Yap HY, Kau SW, Fraschini G, Ewer MS, Chawla SP, Benjamin RS. Hortobagyi GN, et al. Am J Clin Oncol. 1989 Feb;12(1):57-62. doi: 10.1097/00000421-198902000-00014. Am J Clin Oncol. 1989. PMID: 2643296 Clinical Trial.

5

Ten-year results of FAC adjuvant chemotherapy trial in breast cancer.

Buzdar AU, Kau SW, Smith TL, Hortobagyi GN. Buzdar AU, et al. Among authors: hortobagyi gn. Am J Clin Oncol. 1989 Apr;12(2):123-8. doi: 10.1097/00000421-198904000-00007. Am J Clin Oncol. 1989. PMID: 2705401

6

Analysis of dose intensity in doxorubicin-containing adjuvant chemotherapy in stage II and III breast carcinoma.

Ang PT, Buzdar AU, Smith TL, Kau S, Hortobagyi GN. Ang PT, et al. Among authors: hortobagyi gn. J Clin Oncol. 1989 Nov;7(11):1677-84. doi: 10.1200/JCO.1989.7.11.1677. J Clin Oncol. 1989. PMID: 2809682

7

Bilateral primary breast cancer in patients treated with adjuvant therapy.

Berté E, Buzdar AU, Smith TL, Hortobagyi GN. Berté E, et al. Among authors: hortobagyi gn. Am J Clin Oncol. 1988 Apr;11(2):114-8. doi: 10.1097/00000421-198804000-00005. Am J Clin Oncol. 1988. PMID: 3128945 Clinical Trial.

8

Use of tamoxifen for breast cancer: twenty-eight years later.

Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. Jaiyesimi IA, et al. Among authors: hortobagyi gn. J Clin Oncol. 1995 Feb;13(2):513-29. doi: 10.1200/JCO.1995.13.2.513. J Clin Oncol. 1995. PMID: 7844613 Review.

9

Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.

Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AU, Hortobagyi GN. Valero V, et al. Among authors: hortobagyi gn. J Clin Oncol. 1995 Dec;13(12):2886-94. doi: 10.1200/JCO.1995.13.12.2886. J Clin Oncol. 1995. PMID: 8523051 Clinical Trial.

10

Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.

Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Greenberg PA, et al. Among authors: hortobagyi gn. J Clin Oncol. 1996 Aug;14(8):2197-205. doi: 10.1200/JCO.1996.14.8.2197. J Clin Oncol. 1996. PMID: 8708708

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,104 results

Search Page